Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05215340
Title	Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)
Acronym	TROPION-Lung08
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Daiichi Sankyo, Inc.
Indications	lung non-small cell carcinoma
Therapies	Pembrolizumab Datopotamab deruxtecan + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG